Clinical Trials
15 trialsNCT04564898 2026-05-20
TriComB
Gruppo Oncologico del Nord-Ovest
Phase 1/2 Active not recruiting
NCT04550897 2026-05-13
BM7PE
Oslo University Hospital
Phase 1/2 Terminated
NCT05759728 2026-01-13
A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
Carina Biotech Limited
Phase 1/2 Recruiting
NCT04031872 2025-09-05
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
The Netherlands Cancer Institute
Phase 1/2 Withdrawn
NCT05589597 2025-08-22
AUDREY
Enterome
Phase 1/2 Terminated
NCT07012954 2025-06-24
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
Sun Yat-sen University
Phase 1/2 Recruiting
NCT04940546 2024-12-03
Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients
Sun Yat-sen University
Phase 1/2 Active not recruiting
NCT06379399 2024-04-23
Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC
Zhejiang Cancer Hospital
Phase 1/2 Unknown
NCT03439462 2024-01-02
Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer
Aadi Bioscience, Inc.
Phase 1/2 Completed
NCT04751955 2023-10-31
A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)
Korean Cancer Study Group
Phase 1/2 Withdrawn
NCT04790448 2023-02-15
Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 1/2 Completed
NCT04368507 2022-11-14
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients
CellabMED
Phase 1/2 Completed
NCT03531632 2022-02-08
MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer
MacroGenics
Phase 1/2 Completed
NCT03470350 2019-07-24
EORTC1615
The Netherlands Cancer Institute
Phase 1/2 Withdrawn
NCT01955629 2016-04-18
AMOR
Sanofi
Phase 1/2 Terminated